Perspectives in genetic counseling for spinal muscular atrophy in the new therapeutic era: early pre-symptomatic intervention and test in minors

[1]  R. Finkel,et al.  Neurofilament as a potential biomarker for spinal muscular atrophy , 2019, Annals of clinical and translational neurology.

[2]  D. Zafeiriou,et al.  Prenatal aspects in spinal muscular atrophy: From early detection to early presymptomatic intervention. , 2018, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[3]  E. Tizzano,et al.  Utility of two SMN1 variants to improve spinal muscular atrophy carrier diagnosis and genetic counselling , 2018, European Journal of Human Genetics.

[4]  R. Finkel,et al.  Treatment Algorithm for Infants Diagnosed with Spinal Muscular Atrophy through Newborn Screening , 2018, Journal of neuromuscular diseases.

[5]  E. Aller,et al.  Correlation between SMA type and SMN2 copy number revisited: An analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases , 2018, Neuromuscular Disorders.

[6]  R. Finkel,et al.  Nusinersen versus Sham Control in Later‐Onset Spinal Muscular Atrophy , 2018, The New England journal of medicine.

[7]  Craig McDonald,et al.  Natural history of infantile‐onset spinal muscular atrophy , 2017, Annals of neurology.

[8]  F. Boardman,et al.  Newborn genetic screening for spinal muscular atrophy in the UK: The views of the general population , 2017, Molecular genetics & genomic medicine.

[9]  R. Finkel,et al.  Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics , 2017, Neuromuscular Disorders.

[10]  W. Chung,et al.  Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care , 2017, Neuromuscular Disorders.

[11]  Brian K. Kaspar,et al.  Single‐Dose Gene‐Replacement Therapy for Spinal Muscular Atrophy , 2017, The New England journal of medicine.

[12]  R. J. Ramamurthi,et al.  Nusinersen versus Sham Control in Infantile‐Onset Spinal Muscular Atrophy , 2017, The New England journal of medicine.

[13]  Y. Chien,et al.  Presymptomatic Diagnosis of Spinal Muscular Atrophy Through Newborn Screening , 2017, The Journal of pediatrics.

[14]  W. Chung,et al.  Pilot study of population-based newborn screening for spinal muscular atrophy in New York state , 2017, Genetics in Medicine.

[15]  R. Finkel,et al.  Spinal muscular atrophy: A changing phenotype beyond the clinical trials , 2017, Neuromuscular Disorders.

[16]  E. Tizzano,et al.  Social/economic costs and health-related quality of life in patients with spinal muscular atrophy (SMA) in Spain , 2017, Orphanet Journal of Rare Diseases.

[17]  Y. Hua,et al.  A-44G transition in SMN2 intron 6 protects patients with spinal muscular atrophy , 2017, Human molecular genetics.

[18]  K. Talbot,et al.  The clinical landscape for SMA in a new therapeutic era , 2017, Gene Therapy.

[19]  W. Hwu,et al.  Efficacy and safety of nusinersen in infants with presymptomatic spinal muscular atrophy (SMA): Interim results from the NURTURE study , 2017 .

[20]  N. King,et al.  New treatments for serious conditions: ethical implications , 2017, Gene Therapy.

[21]  F. Griffiths,et al.  Newborn screening for spinal muscular atrophy: The views of affected families and adults , 2017, American journal of medical genetics. Part A.

[22]  A. Hoischen,et al.  Neurocalcin Delta Suppression Protects against Spinal Muscular Atrophy in Humans and across Species by Restoring Impaired Endocytosis. , 2017, American journal of human genetics.

[23]  L. H. van den Berg,et al.  Association of motor milestones, SMN2 copy and outcome in spinal muscular atrophy types 0–4 , 2017, Journal of Neurology, Neurosurgery & Psychiatry.

[24]  R. Touraine,et al.  Type 0 Spinal Muscular Atrophy: Further Delineation of Prenatal and Postnatal Features in 16 Patients. , 2016, Journal of neuromuscular diseases.

[25]  E. Tizzano,et al.  Genotype-phenotype correlation of SMN locus genes in spinal muscular atrophy children from Argentina. , 2016, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[26]  R. Finkel,et al.  Developmental milestones in type I spinal muscular atrophy , 2016, Neuromuscular Disorders.

[27]  M. Walter,et al.  Disease burden of spinal muscular atrophy in Germany , 2016, Orphanet Journal of Rare Diseases.

[28]  R. Finkel,et al.  Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trials , 2015, Neuromuscular Disorders.

[29]  Jennifer L Taylor,et al.  Newborn screening for spinal muscular atrophy: Anticipating an imminent need. , 2015, Seminars in perinatology.

[30]  J. Carulli,et al.  Newborn blood spot screening test using multiplexed real-time PCR to simultaneously screen for spinal muscular atrophy and severe combined immunodeficiency. , 2015, Clinical chemistry.

[31]  W. Chung,et al.  Observational study of spinal muscular atrophy type I and implications for clinical trials , 2014, Neurology.

[32]  M. Barceló,et al.  Improving detection and genetic counseling in carriers of spinal muscular atrophy with two copies of the SMN1 gene , 2014, Clinical genetics.

[33]  Jun Zhu,et al.  An Ashkenazi Jewish SMN1 haplotype specific to duplication alleles improves pan-ethnic carrier screening for spinal muscular atrophy , 2013, Genetics in Medicine.

[34]  R. Finkel.  Electrophysiological and motor function scale association in a pre-symptomatic infant with spinal muscular atrophy type I , 2013, Neuromuscular Disorders.

[35]  W. Chung,et al.  Prospective cohort study of spinal muscular atrophy types 2 and 3 , 2012, Neurology.

[36]  N. Nagan,et al.  Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72 400 specimens , 2011, European Journal of Human Genetics.

[37]  C. Hernández-Chico,et al.  Plastin 3 expression in discordant spinal muscular atrophy (SMA) siblings , 2011, Neuromuscular Disorders.

[38]  S. Borrego,et al.  The c.859G>C variant in the SMN2 gene is associated with types II and III SMA and originates from a common ancestor , 2010, Journal of Medical Genetics.

[39]  M. Rich,et al.  Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN , 2010, Nature Biotechnology.

[40]  Y. Hua,et al.  A positive modifier of spinal muscular atrophy in the SMN2 gene. , 2009, American journal of human genetics.

[41]  A. Clarke,et al.  Genetic testing in asymptomatic minorsBackground considerations towards ESHG Recommendations , 2009, European Journal of Human Genetics.

[42]  E. Aller,et al.  Mutation update of spinal muscular atrophy in Spain: molecular characterization of 745 unrelated patients and identification of four novel mutations in the SMN1 gene , 2009, Human Genetics.

[43]  B. Wirth,et al.  Survival motor neuron gene 2 silencing by DNA methylation correlates with spinal muscular atrophy disease severity and can be bypassed by histone deacetylase inhibition , 2008, Human molecular genetics.

[44]  W. Nyka,et al.  Unaffected patients with a homozygous absence of the SMN1 gene , 2008, European Journal of Human Genetics.

[45]  B. Wirth,et al.  Plastin 3 Is a Protective Modifier of Autosomal Recessive Spinal Muscular Atrophy , 2008, Science.

[46]  B. Wirth,et al.  Mildly affected patients with spinal muscular atrophy are partially protected by an increased SMN2 copy number , 2006, Human Genetics.

[47]  Mark B Bromberg,et al.  Natural history of denervation in SMA: Relation to age, SMN2 copy number, and function , 2005, Annals of neurology.

[48]  I. Cusco,et al.  A genetic and phenotypic analysis in Spanish spinal muscular atrophy patients with c.399_402del AGAG, the most frequently found subtle mutation in the SMN1 gene , 2003, Human mutation.

[49]  M. Barceló,et al.  Prenatal diagnosis for risk of spinal muscular atrophy , 2002, BJOG : an international journal of obstetrics and gynaecology.

[50]  A. Munnich,et al.  Structure and organization of the human survival motor neurone (SMN) gene. , 1996, Genomics.

[51]  K. Zerres,et al.  Natural history in proximal spinal muscular atrophy. Clinical analysis of 445 patients and suggestions for a modification of existing classifications. , 1995, Archives of neurology.

[52]  J. Weissenbach,et al.  Identification and characterization of a spinal muscular atrophy-determining gene , 1995, Cell.

[53]  N. Leschot,et al.  Unusual pedigree patterns in seven families with spinal muscular atrophy; further evidence for the allelic model hypothesis , 1986, Clinical genetics.

[54]  Wilson Jm,et al.  Principles and practice of mass screening for disease , 1968 .

[55]  J. M. Wilson,et al.  [Principles and practice of mass screening for disease]. , 1968, Boletin de la Oficina Sanitaria Panamericana. Pan American Sanitary Bureau.